Exact Sciences to Webcast Investor & Analyst Day

MADISON, Wis.--()--Exact Sciences Corp. (Nasdaq: EXAS) today announced that it will provide a live video webcast and conference call for its Investor & Analyst Day on June 25.

The event will focus on the Exact Sciences’ strong foundation for growth, including Cologuard and Exact Sciences Laboratories and customer care center; the company’s multi-faceted commercial strategy to continue to drive growth; and its compelling product pipeline, including the company’s recently announced partnership with The University of Texas MD Anderson Cancer Center to develop a blood test for lung cancer. The agenda features presentations and discussions with company executives and leaders from MD Anderson and Mayo Clinic.

Investor & Analyst Day Webcast and Conference Call Details

    Date:           Thursday, June 25, 2015
Time:

8:30 a.m.-1 p.m. ET, 7:30 a.m.-12 p.m. CT

Webcast:

The video webcast can be accessed at www.exactsciences.com

Telephone: Domestic callers, dial 877-212-6082
International callers, dial 707-287-9332
Access code for both domestic and international callers: 68320710
 

An archive of the webcast will be available at www.exactsciences.com. A replay of the conference call will be available by calling 855-859-2056 domestically or 404-537-3406 internationally. The access code for the replay is 68320710. The webcast, conference call and replay are open to all interested parties.

About Exact Sciences Corp.

Exact Sciences Corp. is a molecular diagnostics company focused on colorectal cancer. The company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. Stool-based DNA technology is included in the colorectal cancer screening guidelines of the American Cancer Society and the U.S. Multi-Society Task Force on Colorectal Cancer. For more information, please visit the company’s website at www.exactsciences.com.

Certain statements made in this news release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended that are intended to be covered by the “safe harbor” created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “could,” “seek,” “intend,” “plan,” “estimate,” “anticipate” or other comparable terms. Forward-looking statements in this news release may address the following subjects among others: statements regarding the sufficiency of our capital resources, our ability to secure favorable reimbursement rates from third-party payers, timing of our launch of a commercial product, our estimates of the available market size and our potential penetration, expected research and development expenses, expected general and administrative expenses and our expectations concerning our business strategy. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10-K and our subsequently filed Quarterly Reports on Form 10-Q. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

Contacts

Exact Sciences Corp.
J.P. Fielder
Senior Director, Corporate Communications
608-210-5220
jpfielder@exactsciences.com

Release Summary

Exact Sciences will webcast its Investor & Analyst Day on June 25.

Contacts

Exact Sciences Corp.
J.P. Fielder
Senior Director, Corporate Communications
608-210-5220
jpfielder@exactsciences.com